Indeed, the promise of CaMKII inhibition for simultaneous prevention of HF progression and development of arrhythmias justifies the development of more specific CaMKII inhibitors that will further both basic research studies and drug development (Westenbrink et al., 2013). This evidence concerns the gene CAMK2G and hydrops fetalis.